Gujarat Kidney IPO Analyzed

Key Points

• Gujarat Kidney IPO received strong investor interest.
• Subscription rate reached 3.7 times, with retail investors leading.
• QIBs showed limited interest, subscribing only 46%.
• Grey market premium: ₹2.2 per share (2.2%).
• Brokerage ratings: Mostly ‘Neutral’, reflecting fair valuation.
• IPO aims to raise ₹250.80 crore, listing on December 30th.

The Gujarat Kidney and Super Speciality IPO, which began on December 23rd, 2025, is getting a good response from investors. This company runs hospitals and offers healthcare services. Investors are eagerly buying shares in the IPO, which gives a few people ownership in the company.

Data from the National Stock Exchange (NSE) shows that by 12:20 PM on Wednesday, December 24th, 2025, investors requested 49.16 million shares. The company was only offering 13.22 million shares. This means that the subscription rate is about 3.7 times, meaning investors wanted 3.7 times more shares than were available.

People who bought things in regular amounts (retail investors) wanted shares the most! They asked for 14.15 times more shares than the company offered. Non-professional investors also showed some interest, but not as much. However, the people who were chosen to invest as big, important investors (Qualified Institutional Buyers or QIBs) didn’t buy many shares – only 46% of what they could.

Another important thing to know is that the shares of Gujarat Kidney were trading for a little more than the price the company wanted to sell them for in the market before the IPO. Sources tracking unofficial markets said Gujarat Kidney’s unlisted shares were trading at ₹116.4, which is a little higher than the planned price range. This extra value is called a grey market premium.

Experts have looked at the IPO and given their opinions. Arihant Capital Markets gave the IPO a “Neutral” rating, meaning they don’t think it’s a great investment right now. They said the price is too high compared to how much the company makes money. SBI Securities also gave a “Neutral” rating, agreeing that the company’s shares are fairly priced.

The company’s history isn’t very long. In February 2024, they started running a hospital called Parekhs Hospital. Because they’re new, there’s a risk that things might not go as planned when they try to make this hospital even better. Brokers said that this could be a problem.

Gujarat Kidney wants to raise ₹250.80 crore, which is a lot of money. They want to use this money to buy a new hospital in Ahmedabad (Parekhs Hospital), pay for another hospital (Ashwini Medical Centre), and buy more shares in another company they own (Harmony Medicare). They also plan to build a new hospital in Vadodara, buy special equipment for their hospitals, and pay back some loans.

The IPO is open from December 23rd to December 24th, 2025. The company will decide which investors get to own the shares on Friday, December 26th, 2025. Investors will get their shares by December 29th, 2025, and the shares will start trading on the NSE and BSE on December 30th, 2025.

MUFG Intime is in charge of making sure the IPO goes smoothly, and Nirbhay Capital Services is helping to sell the shares. Remember, the ideas about the IPO come from the company and the experts, and we shouldn’t take them as guarantees.

“Investing in companies is like planting a seed – you hope it will grow and become something valuable over time.”